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Abstract
Purpose To determine whether the measurement of serum
AMH can be used to diagnose PCOS and as a tool to predict
the prognosis of PCOS.
Methods This is a case–control study. Women of reproductive
age (18–35 years) were recruited consecutively at a tertiary
academic hospital during the period of March 2009–October
2011 and were divided into case (PCOS patients defined by
the Rotterdam criteria) and control groups (non-PCOS
patients). Menstrual history, clinical manifestations of
hyperandrogenism, ovarian ultrasound assessments, and the
levels of AMH, LH, FSH, and estradiol were collected.
Results Seventy-one cases and 71 controls were recruited.
AMH serum levels were significantly higher in PCOS patients
than in controls. The Area Under the Curve (AUC) of the
serum AMH assay in PCOS patients reached a value of 0.870.
With a cut-off value of 4.45 ng/ml, the serum AMH level had
a sensitivity of 76.1 % and a specificity of 74.6 %. The most
common phenotypes of PCOS in this study were anovulation
and polycystic ovary (63.4 %). However, the mean level of
AMH was highest in the phenotypes of anovulation, polycys-
tic ovaries and hyperandrogenism (11.1 ng/ml).
Conclusions In Indonesian women, AMH can be used as an
alternative diagnostic criteria for PCOS patients with a cut-off
value of 4.45 ng/ml. AMH value rise when hyperandrogenism
is present therefore serum AMH levels also reflect the pheno-
type of PCOS. However, these findings must be confirmed
with larger clinical studies.
Keywords AMH .PCOS .Diagnosis of PCOS . Prognosis of
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Introduction
Polycystic ovary syndrome (PCOS) is a frequently encoun-
tered problem in reproductive endocrinology, affecting appro-
ximately 6 % of women in reproductive age [1]. Abnormalities
of reproductive hormones can trigger anovulatory cycles,
resulting in infertility and menstrual disorders [2]. Based on
the 2003 Rotterdam consensus, the three diagnostic criteria of
PCOS are oligo-and/or anovulation (OA), hyperandrogenism
(either clinical or biochemical) (HA), and the ultrasound fea-
ture of polycystic ovaries (PCO) [3]. A diagnosis is made in the
presence of at least two criteria, after excluding diseases asso-
ciated with excessive androgen production. Based on these
criteria, we were able to acknowledge four different pheno-
types in PCOS: phenotype A (OA+HA+PCO); phenotype B
(HA+OA), phenotype C (HA+PCO), and phenotype D (OA+
PCO) [3]. The majority of patients with PCOS also have
metabolic disorders, such as insulin resistance, that result in
hyperinsulinemia, obesity, and dyslipidemia [4].
Anti-Mullerian hormone (AMH) has a glycoprotein dimer
structure and is a member of the transforming growth factor-β
(TGF-β) family. AMH is produced by the granulosa cells
surrounding preantral and antral follicles and has an important
role in the development andmaturation of follicles [2]. Several
studies have suggested that AMH serum levels may be a
marker for polycystic ovary syndrome (PCOS). As the diag-
nostic criteria for ultrasound findings is the presence of more
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than 12 follicles with a diameter of 2–9 mm or when the
ovarian volume is more than 10 cm3 [3], it may correlate with
the level of serum AMH.
The level of AMH circulating in the blood is not affected
by the menstrual cycle nor altered during the use of oral
contraceptives, therefore it can be used as a potential biolog-
ical marker for PCO or PCOS [5]. AMH expression occurs
after deployment of the follicle and continues through the
antral phase of follicle development. It suppresses the produc-
tion of follicle-stimulating hormone (FSH) and affects follic-
ular growth by inhibiting the expression of aromatase-
dependent FSH and luteinizing hormone (LH) receptor [6].
AMH production by granulosa cells in the polycystic ovary
is 75 times higher compared to healthy women. AMH levels
in the plasma of PCOS patients are two or three times higher
than average and begin to decline five years later than healthy
women [6]. Weerakiet’s et al. stated that AMH plasma levels
can be a marker of the degree to which folliculogenesis is
impaired in patients with PCOS [7].
In patients with PCOS, there is a barrier that keeps follicles
from becoming the dominant follicle. In addition to the very
low levels of FSH, high levels of AMH decrease the sensitiv-
ity of follicles to FSH. Thus, follicles cannot develop into a
dominant follicle, which leads to an accumulation of small
antral follicles 2–9 mm in diameter [8]. AMH also inhibit the
activity of the aromatase enzyme, suggesting that AMH con-
tributes to the severity of PCOS [9].
A study by Dewailly et al. indicated that AMHmay also be
used as a surrogate marker of classical hyperandrogenism
[10]. Several other studies emphasize that the concentration
of AMH is associated with the severity of morphological and
hormonal changes in PCOS patients. Skalba et al. found
significant differences in AMH and LH in PCOS patient.
AMH levels are associated with free-testosterone, androstene-
dione, and the free androgen index (FAI) in PCOS patients
and non-PCOS patients [11].
Currently there are no studies in Indonesia focusing on the
association between the phenotype of PCOS patients and
serum AMH levels. The purpose of this study was to compare
serum levels of AMH in PCOS and normo-ovulatory patients
and to determine the relationship of serum AMH levels with
clinical parameters, hormonal levels and ultrasound features
in PCOS patients.
Materials and methods
This is a case–control study. Our study population were wom-
en of reproductive age (18–35 years) recruited consecutively at
tertiary academic hospital Jakarta during the period of March
2009–October 2011 and agreed to participate in this study.
Cases were women who met the diagnostic criteria for
PCOS. Subjects who received hormonal therapy within three
months before the beginning of the study were excluded.
Diagnosis of PCOS was established based on Rotterdam
2003 consensus, which is the finding of 2 out of the 3 follow-
ing cr i t e r i a : (1) o l igo and/or anovula t ion ; (2 )
hyperandrogenism, defined as hirsutism (Ferriman-Gallwey
score>8), or minor signs such as acne, seboborrhea; and (3)
criteria for polycystic ovary by ultrasound examination (min-
imum of 12 follicles with 2–9 mm diameters in each ovary
and/or increasing ovarian volume with a minimum size of
10 mm3) [12]. Clinical evaluation and ultrasonography exam-
ination were performed by authors who specialized in repro-
ductive endocrinology. Laboratory examination was conduct-
ed in tertiary academic hospital Jakarta, Indonesia. PCOS
patients fulfilling the diagnostic criteria were then classified
to their corresponding PCOS phenotypes (A/B/C/D). In-
formed consent was obtained from all women, and approval
from the Human Ethics Committee of Faculty of Medicine
Universitas Indonesia was obtained.
The control group consisted of women without endometri-
osis, cysts, or other ovarian gynecological disorders; had
regular menstrual cycles (26–35 days); did not have endocrine
abnormalities (prolactin, FSH, and basal estradiol at normal
levels and not in a state of hyperandrogenism); and had
morphologically normal ovaries according to ultrasound.
Women with tubal factors were included in the control group.
Secondary data from medical records were used to obtain
data on the subject’s menstrual cycle, physical examination,
ultrasound and laboratory. AMH levels weremeasured by using
the Gen II enzyme-linked immunosorbent assay (ELISA) with
units of ng/ml. A condition of hyperandrogenemia in the sub-
ject was assessed by the Free Androgen Index (FAI), namely,
testosterone levels (nmol/L) divided by the levels of Sex-
Hormone Binding Globulin (SHBG). Subjects in this study
were classified as having hyperandrogenemia if the FAI was
>5 [13]. Body mass index (BMI) was defined as weight in
kilograms divided by height in meters squared (kg/m2). Normal
weight is defined as having a body mass index (BMI) value of
18.5 - 24.9 kg/m2, and overweight is a BMI>25.0 kg/m2 [14].
Other components measured were: 1) levels of total testoste-
rone (T), 2) fasting glucose-fasting insulin (FGFI), and 3) serum
FSH, LH, and PRL.
Data analyses were performed with Statistical Program for
Social Sciences (SPSS) version 11.0 (Chicago, Illinois). We
calculated the frequency of each PCOS phenotype. Differ-
ences in age, FAI, LH-FSH ratio, BMI, LH, AMH, and FSH
level were analyzed using independent t-tests for data with
normal distribution and non-parametric Mann Whitney test
for data that were not normally distributed. Cut-off values of
basal AMH levels as a predictor of the diagnosis and progno-
sis of PCOS were analyzed using a Receiver Operating Char-
acteristic (ROC) procedure. The relationship between AMH
levels and PCOS phenotypes were assessed byKruskal-Wallis
test. Multivariate logistic regression analyses were used to
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study the association between variables and PCOS. Backward
selection of parameters was applied, using P<0.05 for entry or
deletion, respectively. The area under the receiver operating
characteristic curve (ROC AUC) was computed to assess the
predictive accuracy of the logistic models, yielding values
from 0.5 (no predictive power) to 1.0 (perfect prediction).
Results
In this study, we obtained 71 subjects diagnosed with PCOS
based on Rotterdam criteria and 71 controls. All variables
compared between these groups are shown in Table 1.
The median age in the PCOS group was significantly lower
than controls. There were also statistically significant differ-
ences between the PCOS and the control group in median/
mean AMH, LH, and FSH levels. The mean body mass index
(BMI), estradiol, and prolactin levels were comparable in both
groups.
We used the ROC curve to investigate the diagnostic po-
tential of AMH level. The AUC of AMH level was 0.870
(95 % CI 0.81–0.92) and optimal AMH cut-off level was
4.45 ng/ml, yielding 76.1 % sensitivity and 74.6 % specificity.
AMH also provided the highest sensitivity and specificity
compared to other variables (Fig. 1). After determining the
cut-off value for AMH level, we found the odds ratios of
AMH level was 9.35 (95 % CI 4.36–20.07) (Table 2).
Based on logistic regression, variables that can be used as a
diagnostic tools in PCOS patients were AMH, LH and FSH
serum level. The strength of the association can be seen from
the value of OR (EXP[B]). AMH had a highest strength of
association (OR=6.80) compared to the serum LH and FSH
level (OR=5.90 and 4.90). We propose a logistic regression
model probability of PCOS:
=1/(1+2.7–[-2.673+1.917(AMH)+1.774(LH)+1.589(FSH]).
ROC curve was used to assess the quality of equation
obtained based on discrimination parameter. AUC value of
the equation was 84.6 %. Cut-off level of 0.49 yielded 83 %
sensitivity and 80.1 % specificity.
The most frequent PCOS phenotypes in this study was
phenotype D (OA+PCO) (63.4 %). Women with PCOS phe-
notype A (OA+HA+PCO) had the highest AMH level
(11.1 ng/ml), and it was significantly higher compared to
AMH level in phenotype D. (Table 3).
Discussion
In this study, the average age of PCOS patients was signifi-
cantly younger than non-PCOS patients (p=0.008). This find-
ing is consistent with studies by Rousseau et al. [15] and
Johnstone et al. [16], who both reported that the proportion
of women with PCO decreased with age [16]. This can be
caused by a decrease in the number of antral follicles through-
out the reproductive years that occurs in normal women, a
phenomenon that also applies to patients with PCOS [13].
Murphy et al. also reported that half of the women diagnosed
with PCOS an average age of 30 years, no longer exhibited
these phenotypes 8 years later [17].
The mean body mass index (BMI) of PCOS patients was
comparable with the control group. Lim et al. reported that
obesity prevalence in PCOS was lower in Asian women than
Caucasian women [18]. However, clinical evaluation and
management of obesity is still an important in PCOS women
and should be assessed in each patient.
We found significantly higher serum AMH levels in PCOS
women compared to the controls. The OR of serum AMH
level was 9.35 (95 % CI 4.36–20.07), meaning that patients
with higher AMH levels (≥4.45 ng/ml) have 9.35 times higher
possibility to suffer from PCOS compared to patients with low
AMH. This finding has consistently been reported in numer-
ous studies [14, 19–24]. This increase is due to increased
synthesis and secretion of AMH by polycystic ovaries [14].
Pellat et al. reported that AMH production increases approx-
imately 75 times higher in each polycystic ovarian granulosa
cell [25]. This finding is supported by Catteau-Jonard et al.,
who found increased mRNA expression of AMH in ovarian
granulosa cells [26]. Elevated serum AMH levels in PCOS
patients may also be caused by disturbances im
folliculogenesis, resulting in the accumulation of excessive
pre-antral and small antral follicles [27]. Cessation of antral
follicle development toward the dominant follicle is due to
suppression of aromatase activity by AMH and by lower
follicle sensitivity to FSH [28, 29].
FSH level was significantly lower in PCOS patients when
compared to controls (p<0.001). According to Pellat et al.,
Table 1 The differences of basal hormone levels, age and BMI between
PCOS and non-PCOS patients
Variables PCOS (n=71) Non-PCOS (n=71) p value
Age (years) 29.55±3.94 31.86±3.88 0.008a
BMI (kg/m2) 25.86 (17.85–39.14) 25.00±5.77 0.072b
AMH (ng/ml) 9.50±5.11 3.53±1.95 <0.001a
FSH (IU/L) 5.39±1.47 6.30 (1.70–17.20) <0.001b
LH (IU/L) 10.41±8.12 4.37 (1.20–11.20) <0.001b
Estradiol (pg/ml) 38.00 (5.42–191.00) 41.50 (12.00–179.00) 0.051b
Prolactin (ng/ml) 9.85 (3.10–20.00) 13.40±4.02 0.076b
a Non parametric Mann Whitney test, significant at the level of <0.05
b Independent t-test, significant at the level of <0.05
*normally distributed data are expressed as mean±standard deviation,
while non-normally distributed data are expressed as median (mini-
mum—maximum)
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FSH does not have an effect on AMH production and mRNA
expression of AMH in granulosa cells, but there is a signifi-
cant reduction (up to 30 %) in AMH after FSH administration
in PCOS patients [6, 29]. The reason for this reduction is yet to
be investigated. LH levels in PCOS patients are also signifi-
cantly higher when compared to non-PCOS patients
(p<0.001). Pigny et al. stated that there was an apparent
correlation between AMH and LH because they found that
LH was elevated in patients with PCOS who also had very
high AMH levels [22, 24, 25].
Until now, the cause of increased AMH levels in PCOS
patients is still inconclusive. One theory stated that high levels
of androgens may be the cause of PCOS. Pellatt et al. said that
there is a relationship between AMH and androgens as AMH
levels are elevated in PCOS patients with hyperandrogenism
[28, 29]. FAI levels are also increased in PCOS patients [20].
Laven et al. stated that significant relationships between serum
AMH levels and increasing testosterone, LH levels, and in-
creased number of follicles and ovarian volume on ultrasound
examination [30].
Measurement of serum AMH levels as a diagnostic modal-
ity of PCOS turned out to have a high sensitivity and speci-
ficity. The AUC of the serum AMH assay in PCOS patients
reached a value of 0.870 (95 % CI 0.81–0.92). Optimal
specificity and sensitivity were achieved at the cutoff level
of 4.45 ng/mL. Nowadays the DSL Assay for measurement of
AMH has been replaced by the Gen II Assay/Beckman Coul-
ter in many countries worldwide. Results for AMH may vary
depending on the assay used. However there have been no
studies comparing these methods, but there are many papers
published using these methods individually.
This study showed that AMH could be used as an alternative
diagnostic tool in PCOS patients. Pigny et al. found that the
specificity and sensitivity of serumAMHmeasurement reached
92 and 67 %, respectively [31]. Lin et al. obtained the cutoff
AMH level of 7.3 ng/mL, giving 76 % specificity 76 % and
70 % sensitivity to predict PCOS [32]. We obtained a cutoff
value of 4.45 ng/mL, lower than the findings of Lin et al [31].
Based on these findings, if at some time, ultrasound cannot
provide accurate data, the levels of AMH may be used to
Fig. 1 ROC curve of AMH, LH,
and FSH in predicting PCOS. (a)
ROC curve of AMH (AUC
0.870) and LH (AUC 0.736),
larger test result indicates more
positive result. (b) ROC curve of
FSH (AUC 0.707), smaller test
result indicates more positive
result
Table 2 Odds ratio of each
variable Variables PCOS (n %) Non-PCOS (n %) p value OR (CI 95 %)
AMH (ng/ml)≥4.45 54 (38.0) 18 (12.7) <0.001 9.35 (4.36–20.07)
<4.45 17 (12.0) 53 (37.3)
Age (years)<30.5 42 (29.6) 35 (24.6) 0.312 1.49 (0.77–2.89)
≥30.5 29 (20.4) 36 (25.4)
BMI (kg/m2)≥25.1 37 (37.4) 16 (16.2) 0.249 1.63 (0.71–3.73)
<25.1 27 (27.3) 19 (19.2)
LH (IU/L)≥5.39 38 (33.6) 18 (15.9) <0.001 5.41 (2.42–12.10)
<5.39 16 (14.2) 41 (36.3)
FSH (IU/L) <5.85 35 (31.0) 21 (18.6) <0.002 3.33 (1.54–7.21)
≥5.85 19 (16.8) 38 (33.6)
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replace the number of follicles as a diagnostic criterion [32]. In
addition, measurement of serum AMH levels may also be
used as an indicator of PCOS patients’ response to therapeutic
approaches [33], including ovarian response to clomiphene
citrate [34], evaluation after treatment with insulin sensitizers
[24], and monitoring after laparoscopic ovarian drilling [26].
The most frequent PCOS phenotype in our study was
phenotype D (OA+PCO), as much as 63.4 %. These results
are different from the epidemiologic study in Greece by
Diamanti-Kandarakis et al. [35]. In that study, the most com-
mon PCOS phenotype was phenotype A (46.4 %), followed
by phenotype B (39.6 %), while phenotype D only accounted
for 6.8 %. This study shows that Indonesian people tend to be
less hyperandrogenic compared to Caucasians. It has been
reported that the prevalence of hyperandrogenism in Asian
women is less and milder than other races [36, 37].
The highest AMH levels were obtained in phenotype A,
which was 11.1 ng/ml. Average levels of AMH in the pheno-
type A were significantly higher than in phenotype D (p=
0.01). It has been reported that concentrations of serum AMH
correlate with the severity of symptoms [29]. Ovulatory PCOS
patients had lower AMH levels compared to anovulatory
PCOS patients [29, 38]. Increased androgen levels have also
been related with the increased production of AMH in PCOS
patients [20].
PCOS phenotypeswith hyperandrogenism have higher risk
of metabolic or cardiovascular disease, the highest risk being
found in phenotype A and B [39]. As explained before, serum
AMH levels were also higher in these phenotypes. Interest-
ingly enough, serum AMH levels showed positive correlation
with insulin resistance, free androgen index, and LDL choles-
terol levels, and negative correlation with HDL cholesterol
levels [11, 40]. Therefore, measurement of serum AMH levels
may also help predict cardiovascular risk factors in PCOS
patients [11].
In our knowledge, this is the first study addressing
the role of AMH in Indonesian women with PCOS.
However, our sample size was relatively small for each
group, hence the large confidence interval of our results.
This study may be continued with a larger sample size
and age matched controls.
In conclusion, this study showed that AMH levels can be
used as diagnostic and prognostic modalities in PCOS pa-
tients. We propose a logistic regression model probability of
PCOS based on AMH, FSH, and LH levels. The most fre-
quent PCOS phenotype in Indonesian women is phenotype D
(OA+PCO). AMH value rise when hyperandrogenism is
present therefore serum AMH levels also reflect the pheno-
type of PCOS. The highest average AMH level was observed
in phenotype A (OA+HA+PCO). Further research will be
needed to evaluate the relationship of AMH levels with lipid
profiles and metabolic syndromes and to evaluate AMH as a
tool for monitoring the success of PCOS treatment.
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